-transparent.png){kind=logo}
Exposure of purified Hageman factor (HF, Factor XII) to phenylglyoxal hydrate (PHG), an agent reacting with arginine residues in protein, inhibited its coagulant properties upon subsequent exposure of negatively charged agents. Once HF had been exposed to kaolin or ellagic acid, however, subsequent addition of PHG was much less inhibitory. PHG had no effect upon the ability of HF to bind to negatively charged surfaces. PGH also inhibited preparations of activated PTA (Factor XI) and thrombin, and, when incubated with plasma, reduced the titer of coagulable fibrinogen, PTA Christmas factor (Factor IX), antihemophilic factor (Factor VIII), Factor VII, Stuart factor (Factor X), proaccelerin (Factor V) and prothrombin (Factor II), and to a lesser degres, HF.
O D Radnoff, and
H Saito
November 1970,
The Journal of laboratory and clinical medicine,
O D Radnoff, and
H Saito
May 1967,
Thrombosis et diathesis haemorrhagica,
O D Radnoff, and
H Saito
December 1977,
Biochemistry,
O D Radnoff, and
H Saito
December 1960,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
O D Radnoff, and
H Saito
February 1979,
Proceedings of the National Academy of Sciences of the United States of America,
O D Radnoff, and
H Saito
May 1961,
The Journal of clinical investigation,
O D Radnoff, and
H Saito
January 1972,
The Journal of laboratory and clinical medicine,
O D Radnoff, and
H Saito
November 1972,
The Journal of laboratory and clinical medicine,
O D Radnoff, and
H Saito
January 1976,
Methods in enzymology,
O D Radnoff, and
H Saito
March 1983,
Journal of the American Veterinary Medical Association,
